Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2014-07-21 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated July 21, 2014, announcing the launch of a product (Sitavig®) in the US by a partner and the granting of a new patent. It contains business updates, product details, and information about the company and its recent merger. This type of announcement, which is not a formal regulatory filing like a 10-K, a specific financial report (ER, IR), or a shareholder vote result, fits best under the general category for regulatory announcements or press releases that convey material, non-financial operational news. Since it is a general announcement of business developments (product launch, patent grant, merger context) and doesn't fit the specific financial/governance codes, the most appropriate classification is Regulatory Filings (RNS) as a catch-all for significant, non-standard announcements, or potentially a general Investor Relations document. Given the nature of the announcement (product launch and patent news), it is a material event disclosure. RNS is the best fit among the provided options for a general corporate announcement that isn't a specific report type.
2014-07-21 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated July 21, 2014, from BioAlliance Pharma announcing two key events: 1) The launch of their product Sitavig® in the US by their partner Innocutis, and 2) The granting of a new US patent for the product. It also mentions a recent merger to form Onxeo. This type of announcement, detailing business developments, product launches, and intellectual property updates, is typically classified as a general regulatory announcement or news release that doesn't fit the strict definitions of 10-K, ER, or IR. Since it is a specific business update and not a formal financial report, the most appropriate category is Regulatory Filings (RNS), which serves as a general category for such announcements that are not covered by more specific codes like DIV, CAP, or MANG. It is not an Earnings Release (ER) as it focuses on commercial/IP news, not financial results highlights. It is also not a Report Publication Announcement (RPA) because it is the primary content, not just an announcement that a report is available.
2014-07-21 French
Communicated under the obligation to provide permanent information / Other communications
Capital/Financing Update Classification · 99% confidence The document announces a specific financial transaction: the granting of a €10 million loan by the top shareholder to BioAlliance Pharma. This action directly relates to strengthening the company's financial resources and capital structure, especially in the context of an ongoing merger (Onxeo creation). This fits the definition of 'Capital/Financing Update' (CAP), as it details a new debt instrument designed to support R&D programs and operations. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about financing activities.
2014-07-18 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document is a press release dated July 18, 2014, announcing that BioAlliance Pharma is securing a 10 million Euro loan from its primary shareholder, Financière de la Montagne. This action is explicitly described as reinforcing the company's financial resources to support R&D expansion and the upcoming merger into Onxeo. This clearly falls under the category of updates on company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2014-07-18 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated July 3, 2014, announcing that the FDA granted accelerated approval (Enregistrement accéléré) for Beleodaq™ (belinostat) for treating peripheral T-cell lymphoma. It discusses regulatory milestones, financial implications ($25 million milestone payment), and the context of the BioAlliance Pharma/Topotarget merger creating Onxeo. This type of announcement, focusing on a specific regulatory decision, clinical trial outcome, or partnership event, is typically classified as a general Regulatory Filing (RNS) if it doesn't fit a more specific category like Earnings Release (ER) or Capital Update (CAP). Since it is a specific announcement about a regulatory action (FDA approval) that is not a full financial report (like 10-K or IR), and it doesn't directly relate to dividends, management changes, or director dealings, the most appropriate general category for significant, non-standard regulatory news is RNS (Regulatory Filings), which serves as a broad category for important corporate announcements not covered elsewhere. Given the context of a major drug approval announcement, RNS is the best fit among the provided options.
2014-07-03 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document announces the FDA's Accelerated Approval of Beleodaq™ for Topotarget, mentions a milestone payment, and discusses the merger creating Onxeo. This is a significant corporate event announcement related to product development and corporate structure, but it is not a standard periodic financial report (like 10-K or IR), a formal earnings release (ER), or a transcript (CT). It is a press release detailing a major business development. Since it doesn't fit the specific categories like M&A (TAR), Capital (CAP), or Earnings Release (ER), and it is a general corporate announcement, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for significant, non-standard announcements, or potentially a general Investor Presentation (IP) if it were structured as such, but the content strongly suggests a press release about a regulatory milestone. Given the options, RNS is the best fit for a general, non-standard corporate news release that isn't explicitly covered elsewhere.
2014-07-03 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.